Jeff Buchalter
Non-executive Chairman

Jeff joins Inivata after a long and successful career in the bio/pharmaceutical industry most recently as Chief Executive Officer of Archimedes Pharma Ltd.  His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organisations.  He brings extensive commercial and drug development experience in oncology and other therapeutic areas.

Jeff has been recognised for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field.  He has also been a Collaborating Partner in the President’s National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States.

Jeff received a Bachelor of Science Degree in Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University.

Robert Tansley
Non-executive Director

Robert joined Cambridge Innovation Capital as Investment Director in January 2014. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical team for the regulatory approval of Valcyte®. Ten years ago, Robert joined the Cambridge based company Arakis and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and being part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.

Robert qualified in medicine from University College London, he is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.

Nitzan Rosenfeld
Chief Scientific Officer

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Limited, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.

Keith Blundy
Non-executive Director

Keith joined Cancer Research Technology in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £50m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc. in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia.

After completing a PhD at the John Innes Institute and a post-doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development.
Keith has a BSc and PhD in genetics and an MBA from the London Business School.

Jeanne Bolger
Non-executive Director

Jeanne joined Johnson & Johnson Innovation – JJDC, Inc as Vice President, Venture Investments, in February 2013. She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.
Jeanne has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK. In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.

Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Peter Wrighton-Smith
Non-executive Director

Dr Wrighton-Smith is the Chief Executive Officer and Founder of Oxford Immunotec Glob al PLC, a high-growth global diagnostics company focussing on monitoring immune-regulated conditions. Peter has led Oxford Immunotec from the foundation stages, through product development to regulatory approval in over 50 countries, and subsequent worldwide commercialisation via both a kit and a CLIA lab model. Over that time, Oxford Immunotec has raised five rounds of venture funding prior to an IPO on NASDAQ in 2013. Dr Wrighton-Smith has a Masters in Engineering, Economics and Management, and a Doctorate in Medical Engineering, both from University of Oxford.

Simon Cartmell
Non-executive Director

With 35 years pharmaceutical, biotech and medtech experience gained in commercial, product development, supply chain, strategic leadership and corporate executive roles, Simon is a serial entrepreneur in early stage healthcare businesses. As CEO of ApaTech Ltd, a QMUL spinout, he developed a world leader in orthobiologics prior to its sale to Baxter for $330m in March 2010. Prior to joining ApaTech in 2004, Simon was a Main Board Director of Celltech Group plc, serving as CEO, Celltech Pharmaceuticals, prior to which he served as COO of Vanguard Medica (later Vernalis plc). The early part of his career was spent at Glaxo/Glaxo Wellcome plc in a series of senior UK and international commercial, development, supply chain and strategic development leadership roles. Simon is an Operating Partner within the IP Group Life-Science team and represents their interests on several diagnostic, medtech and digital health Boards of Directors as a Non-Executive Director or Chairman, including Inivata. In 2016 Simon was awarded the OBE for services to the healthcare business sector.